Results 251 to 260 of about 31,041 (297)

Molecular mechanism for platelet hyperreactivity in diabetes mellitus

Journal of Diabetes Investigation, EarlyView.
Hideaki Kaneto
wiley   +1 more source

Potential drug-drug interactions among hospitalised cardiac patients in Nepal: a prospective observational study. [PDF]

BMJ Open
Sah BK, Karna AK, Subedi S, Sah RK, Shrestha S, Dangi NB.   +5 more
europepmc   +1 more source

Evaluation of gaps in direct oral anticoagulants (DOACs) management in an outpatient underserved clinic: a cross-sectional study. [PDF]

Sci Rep
Alghamdi BM, Rogers SL.
europepmc   +1 more source

Endovascular treatment of a symptomatic giant partially thrombosed aneurysm with saccular endovascular aneurysm lattice (SEAL) XL: The world's largest novel intrasaccular device. [PDF]

Interv Neuroradiol
Chaudhari A, Lin E, Kamal R, Rosenstein ZM, Ramirez-Abreu DG, Altschul DJ, Jankowitz BT, Pabón B, Zaidat OO.   +8 more
europepmc   +1 more source

Long-Term Outcomes of Invasive vs Noninvasive Treatment for Intermittent Claudication: A Systematic Review and Meta-Analysis. [PDF]

Cochrane Evid Synth Methods
Elmahi A, Elmahi A, Doolan N, Hezima M, Gowey A, Moneley D, McHugh S, Aly S, Naughton P, Kheirelseid EAH.   +9 more
europepmc   +1 more source

Risk factors for unexplained early neurological deterioration after intravenous thrombolysis: a meta-analysis. [PDF]

Neurosciences (Riyadh)
Li J, Zhu CL, Zhang CY, Li LM, Liu R, Zhang S, He ML.   +6 more
europepmc   +1 more source

Correction: Non-persistence with anti-platelet therapy and long-term mortality after ischemic stroke: A nationwide study. [PDF]

PLoS One
PLOS One Staff.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Antiplatelet drugs

Medical Journal of Australia, 1999
Antiplatelet drugs protect against myocardial infarction, stroke, cardiovascular death and other serious vascular events in patients with a history of previous vascular events or known risk factors for cardiovascular disease. Aspirin reduces the risk of serious vascular events in patients at high risk of such an event by about a quarter and is ...
R I, Baker, G J, Hankey
openaire   +3 more sources

Antiplatelet drugs

European Journal of Clinical Investigation, 1994
Abstract.The evidence in support of the safety and efficacy of aspirin in the secondary prevention of platelet dependent vascular occlusion is compelling. The utility of this drug has stalled the development of potential competitors, such as thromboxane antagonists.
G A, Fitzgerald, E A, Meagher
openaire   +2 more sources